CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained over the dosing interval, establishing proof of mechanism Preclinical data and preliminary clinical results support further evaluation of CHS-114 in combination with the anti-programmed cell death protein 1 (PD-1) antibody, toripalimab-tpzi, and other immuno-oncology (IO) agents REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.

CHS-114在经过严重预处理的实体瘤患者中显示出可接受的安全性，没有剂量限制性毒性（DLTs），观察到外周CCR8+调节性T细胞（Tregs）的选择性耗竭，并在给药间隔内维持耗竭，建立了机制证明临床前数据和初步临床结果支持CHS-114与抗程序性细胞死亡蛋白1（PD-1）抗体，托利单抗tpzi和其他免疫肿瘤学（IO）药物REDWOOD CITY，California，2024年5月23日（GLOBE NEWSWIRE）--Coherus BioSciences，Inc.的进一步评估。

(Coherus, Nasdaq: CHRS), today announced clinical data from the CHS-114, single agent dose escalation stage of its Phase 1 study at the ASCO Annual Meeting, taking place May 31 to June 4, 2024, at McCormick Place in Chicago. CHS-114 is a novel afucosylated human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that selectively and potently targets human CCR8 with no off-target binding.

（Coherus，Nasdaq:CHRS），今天在2024年5月31日至6月4日于芝加哥麦考密克广场举行的ASCO年会上宣布了CHS-114单药剂量递增阶段第一阶段研究的临床数据。CHS-114是一种新型的无岩藻糖基化人免疫球蛋白G1（IgG1）单克隆抗体（mAb），可选择性和有效靶向人CCR8，无脱靶结合。

CCR8 is a G protein-coupled receptor (GPCR) that shows preferential expression on tumor resident Treg cells and has promise as a drug target for selectively targeting immune suppression in the tumor microenvironment (TME) without broadly depleting Treg cells, which has the known unwanted side effect of autoimmune activation.

CCR8是一种G蛋白偶联受体（GPCR），在肿瘤驻留的Treg细胞上显示出优先表达，并且有望作为选择性靶向肿瘤微环境（TME）中免疫抑制的药物靶标，而不会广泛消耗Treg细胞，Treg细胞具有已知的不需要的自身免疫激活的副作用。

“The Phase 1 preliminary dose escalation results are an important milestone as we progress our innovative I-O pipeline. We are very pleased with the safety profile, the predictable dose proportional pharmacokinetic profile, and the selective depletion of peripheral CCR8+ Tregs that were observed,” said Rosh Dias, M.D., Coherus’ Chief Medical Officer. “By targeting CCR8, we believe CHS-114 has the potential to overcome Treg immune suppression in the TME and allows T.

“随着我们创新的I-O管道的进展，第一阶段初步剂量递增结果是一个重要的里程碑。我们对观察到的安全性，可预测的剂量比例药代动力学特征以及外周CCR8+Tregs的选择性消耗感到非常满意，”科罗斯首席医官医学博士Rosh Dias说。“通过靶向CCR8，我们相信CHS-114有可能克服TME中的Treg免疫抑制，并允许T。